We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

Back to rankings

123 hedge funds and large institutions have $399M invested in Keryx Biopharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

13% more capital invested

Capital invested by funds: $354M → $399M (+$44.8M)

6% more funds holding

Funds holding: 116 → 123 (+7)

5% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 38

30% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $4.37M

Holders
123
Holders Change
+7
Holders Change %
+6.03%
% of All Funds
3.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
36
Reduced
38
Closed
12
Calls
$3.06M
Puts
$4.37M
Net Calls
-$1.31M
Net Calls Change
-$776K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$7.06M
2
Millennium Management
Millennium Management
New York
+$3.28M
3
BFA
BlackRock Fund Advisors
California
+$1.92M
4
Morgan Stanley
Morgan Stanley
New York
+$1.65M
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$1.48M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.82M
2
State Street
State Street
Massachusetts
-$3.63M
3
PI
Putnam Investments
Massachusetts
-$3.54M
4
CWG
C WorldWide Group
Denmark
-$2.68M
5
SFM
Sphera Funds Management
Israel
-$1.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCB
101
Cutter & Co Brokerage
Missouri
$59K – – –
Prudential Financial
102
Prudential Financial
New Jersey
$59K – – –
Simplex Trading
103
Simplex Trading
Illinois
$41K -$119K -21,841 -76%
Barclays
104
Barclays
United Kingdom
$40K -$191K -34,904 -84%
BlackRock
105
BlackRock
New York
$40K -$6.81K -1,246 -16%
IA
106
IFP Advisors
Florida
$35K – – –
LTFS
107
Ladenburg Thalmann Financial Services
Florida
$35K +$546 +100 +2%
TRCT
108
Tower Research Capital (TRC)
New York
$35K +$32.3K +5,911 New
BNP Paribas Financial Markets
109
BNP Paribas Financial Markets
France
$33K -$5.95K -1,089 -16%
ClearBridge Investments
110
ClearBridge Investments
New York
$23K -$5.46K -1,000 -20%
DADC
111
D.A. Davidson & Co
Montana
$20K – – –
Zurich Cantonal Bank
112
Zurich Cantonal Bank
Switzerland
$19K – – –
AF
113
Allworth Financial
California
$12K – – –
Nisa Investment Advisors
114
Nisa Investment Advisors
Missouri
$9K -$4.92K -900 -36%
MFW
115
Mosaic Family Wealth
Missouri
$9K – – –
CSS
116
Cubist Systematic Strategies
Connecticut
$8K +$7.7K +1,409 New
CG
117
Cutler Group
California
$7K -$20.3K -3,709 -75%
CFA
118
CT Financial Advisors
Pennsylvania
$6.07K – – –
FANJ
119
Financial Architects (New Jersey)
New Jersey
$2K – – –
HI
120
Hudock Inc
Pennsylvania
$2K +$1.91K +350 New
GAM
121
Gemmer Asset Management
California
$1K – – –
PHK
122
Point72 Hong Kong
Hong Kong
$1K +$546 +100 New
SPIA
123
Steward Partners Investment Advisory
New York
$1K +$1.64K +300 New
PI
124
Putnam Investments
Massachusetts
– -$3.54M -667,400 Closed
SFM
125
Sphera Funds Management
Israel
– -$1.66M -311,600 Closed
2 3 4
5
6

KERX Hedge Fund Activity: Q4 2016 in Review

123 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2016, worth a combined $399M — up 13% from $354M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KERX positions and 12 closed out — a net gain of 7 holders — while 36 added to existing stakes and 38 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $7.06M. The largest seller was Fidelity Investments, cutting an estimated $3.82M.

  • 123 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2016, up from 116 in Q3 2016.
  • Funds reported $399M of Keryx Biopharmaceuticals Inc stock for Q4 2016, up 13% quarter-over-quarter.
  • 19 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2016 and 12 closed out, a net change of +7 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q4 2016 was Deerfield Management, an estimated $7.06M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q4 2016 was Fidelity Investments, an estimated $3.82M sold.

Based on aggregated 13F filings for Q4 2016.